Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
NCT ID: NCT03504852
Last Updated: 2021-10-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
331 participants
INTERVENTIONAL
2018-06-25
2020-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
NCT01365455
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
NCT01412944
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
NCT02074982
Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.
NCT01900782
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
NCT01555125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study consisted of 4 periods: screening (up to 4 weeks), treatment Period 1 (16 weeks), treatment Period 2 (36 weeks), and post-treatment follow-up (8 weeks).
Subjects were randomized using a 1:1 ratio to the following groups: Secukinumab 300 mg every 2 weeks; Secukinumab 300 mg every 4 weeks.
In addition, subjects from the 300 mg every 4 weeks group who did not achieve Psoriasis Area Severity Index (PASI) 90 response at Week 16 were reassigned using a 1:1 ratio to either remain on secukinumab 300 mg every 4 weeks or receive secukinumab 300 mg every 2 weeks starting at Week 16, until the end of treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Secukinumab 300 mg every 2 weeks (Q2W)
2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment.
secukinumab 150 mg
sub-cutaneous secukinumab prefilled syringe 150 mg
Secukinumab 300 mg every 4 weeks (Q4W)
2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter Q4W. Includes both subjects randomized to remain on Q4W the entire treatment period, and subjects that were Psoriasis Area and Severity Index (PASI) 90 responders at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group.
secukinumab 150 mg
sub-cutaneous secukinumab prefilled syringe 150 mg
Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up)
2 injections of secukinumab 150 mg once weekly up to week 4, then Q4W up to Week 16 and thereafter Q2W. Includes Psoriasis Area and Severity Index (PASI) 90 non-responders (NR) at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group (subjects randomized to switch to Q2W if PASI 90 non-responder at Week 16).
secukinumab 150 mg
sub-cutaneous secukinumab prefilled syringe 150 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
secukinumab 150 mg
sub-cutaneous secukinumab prefilled syringe 150 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must have been able to understand and communicate with the investigator and comply with the requirements of the study.
* Men or women at least 18 years of age at time of screening.
* Body weight of ≥ 90 kg at the time of randomization.
* Chronic plaque-type psoriasis present for at least 6 months and diagnosed before randomization.
* Moderate to severe psoriasis as defined at randomization by:
* Psoriasis Area and Severity Index (PASI) score of 12 or greater, and
* Investigator's Global Assessment (IGA) mod 2011 score of 3 or greater (based on a static scale of 0 - 4), and
* Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.
* Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by:
* topical treatment and/or,
* phototherapy and/or,
* previous systemic therapy.
Exclusion Criteria
* Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to. Subjects not willing to limit ultraviolet (UV) light exposure (e.g., sunbathing and / or the use of tanning devices) during the course of the study will be considered not eligible for this study since UV light exposure is prohibited. Note: administration of live vaccines 6 weeks prior to Randomization or during the study period is also prohibited.
* Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting Interleukin-17 (IL-17) or the IL-17 receptor.
* Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 4 weeks until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.
* Pregnant or nursing (lactating) women
* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
* History of hypersensitivity to any of the study drug constituents.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Phoenix, Arizona, United States
Novartis Investigative Site
Rogers, Arkansas, United States
Novartis Investigative Site
Irvine, California, United States
Novartis Investigative Site
Sacramento, California, United States
Novartis Investigative Site
Sacramento, California, United States
Novartis Investigative Site
San Diego, California, United States
Novartis Investigative Site
Santa Monica, California, United States
Novartis Investigative Site
Centennial, Colorado, United States
Novartis Investigative Site
Tampa, Florida, United States
Novartis Investigative Site
West Palm Beach, Florida, United States
Novartis Investigative Site
Alpharetta, Georgia, United States
Novartis Investigative Site
Snellville, Georgia, United States
Novartis Investigative Site
Skokie, Illinois, United States
Novartis Investigative Site
Indianapolis, Indiana, United States
Novartis Investigative Site
New Albany, Indiana, United States
Novartis Investigative Site
Louisville, Kentucky, United States
Novartis Investigative Site
Owensboro, Kentucky, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
New Brighton, Minnesota, United States
Novartis Investigative Site
Saint Joseph, Missouri, United States
Novartis Investigative Site
East Windsor, New Jersey, United States
Novartis Investigative Site
Verona, New Jersey, United States
Novartis Investigative Site
Forest Hills, New York, United States
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
Charlotte, North Carolina, United States
Novartis Investigative Site
Winston-Salem, North Carolina, United States
Novartis Investigative Site
Fairborn, Ohio, United States
Novartis Investigative Site
Oregon City, Oregon, United States
Novartis Investigative Site
Portland, Oregon, United States
Novartis Investigative Site
Charleston, South Carolina, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Mesquite, Texas, United States
Novartis Investigative Site
Pflugerville, Texas, United States
Novartis Investigative Site
San Antonio, Texas, United States
Novartis Investigative Site
Norfolk, Virginia, United States
Novartis Investigative Site
Wenatchee, Washington, United States
Novartis Investigative Site
Madison, Wisconsin, United States
Novartis Investigative Site
Calgary, Alberta, Canada
Novartis Investigative Site
Red Deer, Alberta, Canada
Novartis Investigative Site
Etobicoke, Ontario, Canada
Novartis Investigative Site
Guelph, Ontario, Canada
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Québec, , Canada
Novartis Investigative Site
Prague, Prague 1, Czechia
Novartis Investigative Site
Nový Jičín, , Czechia
Novartis Investigative Site
Bochum, , Germany
Novartis Investigative Site
Frankfurt, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Kiel, , Germany
Novartis Investigative Site
Leipzig, , Germany
Novartis Investigative Site
Debrecen, , Hungary
Novartis Investigative Site
Pécs, , Hungary
Novartis Investigative Site
Szeged, , Hungary
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Modena, MO, Italy
Novartis Investigative Site
Perugia, PG, Italy
Novartis Investigative Site
Siena, SI, Italy
Novartis Investigative Site
Napoli, , Italy
Novartis Investigative Site
Chelyabinsk, , Russia
Novartis Investigative Site
Kazan', , Russia
Novartis Investigative Site
Krasnodar, , Russia
Novartis Investigative Site
Lipetsk, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Saratov, , Russia
Novartis Investigative Site
Yekaterinburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022 Jun;186(6):942-954. doi: 10.1111/bjd.20971. Epub 2022 Apr 8.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
A Plain Language Trial Summary is available on novartisclinicaltrials.com
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-004620-60
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CAIN457A2324
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.